FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948151014> ?p ?o ?g. }

• W2948151014 abstract "Abstract Background Biological agents have allowed remarkable improvement in controlling autoimmune arthropathies, although none of the numerous biologics readily available represent a universal treatment standard. Moreover, classical and genetic predictors are currently unsatisfactory to predict individual response to a biologic, and the best treatment selection is still based on a trial‐and‐error approach. Here, we report a clinical case demonstrating the usefulness of examining the leukocytes’ secretome of patients. We set up and standardized a protocol that examines a patient's immune responses to establish the secretome of the blood mononuclear leukocytes and personalize the biotherapy. Case presentation A 24‐year‐old woman was diagnosed with active early rheumatoid arthritis. The initial treatment regimen (prednisone, methotrexate, hydroxychloroquine, naproxen) was inefficient, as well as the anti‐TNF adalimumab. The diagnosis was revised as possible rheumatoid arthritis‐like psoriatic arthritis and adalimumab was replaced by abatacept (IgG1 Fc‐CTLA‐4) to no avail. Five years later, abatacept was replaced by the anti‐IL‐12/IL‐23 ustekinumab with no objective control over the symptoms. The patient was thus enrolled in a prospective study based on the quantification of cytokines secreted by peripheral blood leukocytes stimulated with well‐known immune activators of pattern recognition receptors and cytokine signalling. The results of this study revealed that plasma concentrations of cytokines were similar between the patient and healthy donors. In comparison to leukocytes from healthy donors, the patient's secretome showed a unique overproduction of IL‐6. The anti‐IL‐6 receptor tocilizumab was, therefore, administered with a rapid improvement of her active psoriatic arthritis that remained dependent on low prednisone dosage. Clinical parameters progressively returned to normal levels and her quality of life was greatly improved, despite the major delay to begin the present personalized treatment. Conclusions An efficient way to effectively treat patients with complex autoimmune arthropathies, and avoid irreversible disability, is to know their leukocytes’ secretome to identify abnormally secreted cytokines and personalize their biotherapy, as exemplified by this case report." @default.
• W2948151014 created "2019-06-14" @default.
• W2948151014 creator A5006861684 @default.
• W2948151014 creator A5013716582 @default.
• W2948151014 creator A5020278481 @default.
• W2948151014 creator A5043390034 @default.
• W2948151014 creator A5049465666 @default.
• W2948151014 creator A5053075978 @default.
• W2948151014 creator A5059609858 @default.
• W2948151014 creator A5087914155 @default.
• W2948151014 date "2019-06-05" @default.
• W2948151014 modified "2023-10-18" @default.
• W2948151014 title "The use of leukocytes’ secretome to individually target biological therapy in autoimmune arthritis: a case report" @default.
• W2948151014 cites W2003165120 @default.
• W2948151014 cites W2020906240 @default.
• W2948151014 cites W2033342396 @default.
• W2948151014 cites W2034332511 @default.
• W2948151014 cites W2041084308 @default.
• W2948151014 cites W2047295937 @default.
• W2948151014 cites W2060500374 @default.
• W2948151014 cites W2073821411 @default.
• W2948151014 cites W2081351081 @default.
• W2948151014 cites W2101005621 @default.
• W2948151014 cites W2118742454 @default.
• W2948151014 cites W2120393706 @default.
• W2948151014 cites W2130631271 @default.
• W2948151014 cites W2156930364 @default.
• W2948151014 cites W2194309244 @default.
• W2948151014 cites W2230558734 @default.
• W2948151014 cites W2342299171 @default.
• W2948151014 cites W23678946 @default.
• W2948151014 cites W2396025051 @default.
• W2948151014 cites W2401255835 @default.
• W2948151014 cites W2572628344 @default.
• W2948151014 cites W2613107140 @default.
• W2948151014 cites W2725127520 @default.
• W2948151014 cites W2734589353 @default.
• W2948151014 cites W2791152077 @default.
• W2948151014 cites W2802137035 @default.
• W2948151014 cites W2806678383 @default.
• W2948151014 cites W2845804275 @default.
• W2948151014 cites W2896927378 @default.
• W2948151014 cites W4210768724 @default.
• W2948151014 doi "https://doi.org/10.1186/s40169-019-0236-7" @default.
• W2948151014 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6548783" @default.
• W2948151014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31165299" @default.
• W2948151014 hasPublicationYear "2019" @default.
• W2948151014 type Work @default.
• W2948151014 sameAs 2948151014 @default.
• W2948151014 citedByCount "5" @default.
• W2948151014 countsByYear W29481510142020 @default.
• W2948151014 countsByYear W29481510142021 @default.
• W2948151014 countsByYear W29481510142022 @default.
• W2948151014 crossrefType "journal-article" @default.
• W2948151014 hasAuthorship W2948151014A5006861684 @default.
• W2948151014 hasAuthorship W2948151014A5013716582 @default.
• W2948151014 hasAuthorship W2948151014A5020278481 @default.
• W2948151014 hasAuthorship W2948151014A5043390034 @default.
• W2948151014 hasAuthorship W2948151014A5049465666 @default.
• W2948151014 hasAuthorship W2948151014A5053075978 @default.
• W2948151014 hasAuthorship W2948151014A5059609858 @default.
• W2948151014 hasAuthorship W2948151014A5087914155 @default.
• W2948151014 hasBestOaLocation W29481510141 @default.
• W2948151014 hasConcept C126322002 @default.
• W2948151014 hasConcept C159654299 @default.
• W2948151014 hasConcept C17991360 @default.
• W2948151014 hasConcept C203014093 @default.
• W2948151014 hasConcept C2776260265 @default.
• W2948151014 hasConcept C2777077863 @default.
• W2948151014 hasConcept C2777138892 @default.
• W2948151014 hasConcept C2777178219 @default.
• W2948151014 hasConcept C2777575956 @default.
• W2948151014 hasConcept C2778886723 @default.
• W2948151014 hasConcept C2778975655 @default.
• W2948151014 hasConcept C2779605438 @default.
• W2948151014 hasConcept C2780132546 @default.
• W2948151014 hasConcept C2780653079 @default.
• W2948151014 hasConcept C2781290027 @default.
• W2948151014 hasConcept C2781413609 @default.
• W2948151014 hasConcept C71924100 @default.
• W2948151014 hasConcept C8891405 @default.
• W2948151014 hasConceptScore W2948151014C126322002 @default.
• W2948151014 hasConceptScore W2948151014C159654299 @default.
• W2948151014 hasConceptScore W2948151014C17991360 @default.
• W2948151014 hasConceptScore W2948151014C203014093 @default.
• W2948151014 hasConceptScore W2948151014C2776260265 @default.
• W2948151014 hasConceptScore W2948151014C2777077863 @default.
• W2948151014 hasConceptScore W2948151014C2777138892 @default.
• W2948151014 hasConceptScore W2948151014C2777178219 @default.
• W2948151014 hasConceptScore W2948151014C2777575956 @default.
• W2948151014 hasConceptScore W2948151014C2778886723 @default.
• W2948151014 hasConceptScore W2948151014C2778975655 @default.
• W2948151014 hasConceptScore W2948151014C2779605438 @default.
• W2948151014 hasConceptScore W2948151014C2780132546 @default.
• W2948151014 hasConceptScore W2948151014C2780653079 @default.
• W2948151014 hasConceptScore W2948151014C2781290027 @default.
• W2948151014 hasConceptScore W2948151014C2781413609 @default.
• W2948151014 hasConceptScore W2948151014C71924100 @default.
• W2948151014 hasConceptScore W2948151014C8891405 @default.
• W2948151014 hasFunder F4320313423 @default.

• next